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Abstract: 
 
Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose and 
lipid metabolism. Agonists of this nuclear receptor are used in the treatment of type 2 diabetes 
and are also studied as a potential treatment of other metabolic diseases, including nonalcoholic 
fatty liver disease. Silymarin, a concentrated phenolic mixture from milk thistle (Silybum 
marianum) seeds, is used widely as a supportive agent in the treatment of a variety of liver 
diseases. In this study, the PPARγ activation potential of silymarin and its main constituents was 
investigated. Isosilybin A (3) caused transactivation of a PPARγ-dependent luciferase reporter in 
a concentration-dependent manner. This effect could be reversed upon co-treatment with the 
PPARγ antagonist T0070907. In silico docking studies suggested a binding mode for 3 distinct 
from that of the inactive silymarin constituents, with one additional hydrogen bond to Ser342 in 
the entrance region of the ligand-binding domain of the receptor. Hence, isosilybin A (3) has 
been identified as the first flavonolignan PPARγ agonist, suggesting its further investigation as a 
modulator of this nuclear receptor. 
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ABSTRACT: Peroxisome proliferator-activated receptor gamma (PPARγ) is a key regulator of glucose and lipid metabolism.
Agonists of this nuclear receptor are used in the treatment of type 2 diabetes and are also studied as a potential treatment of other
metabolic diseases, including nonalcoholic fatty liver disease. Silymarin, a concentrated phenolic mixture from milk thistle
(Silybum marianum) seeds, is used widely as a supportive agent in the treatment of a variety of liver diseases. In this study, the
PPARγ activation potential of silymarin and its main constituents was investigated. Isosilybin A (3) caused transactivation of a
PPARγ-dependent luciferase reporter in a concentration-dependent manner. This effect could be reversed upon co-treatment
with the PPARγ antagonist T0070907. In silico docking studies suggested a binding mode for 3 distinct from that of the inactive
silymarin constituents, with one additional hydrogen bond to Ser342 in the entrance region of the ligand-binding domain of the
receptor. Hence, isosilybin A (3) has been identified as the first flavonolignan PPARγ agonist, suggesting its further investigation
as a modulator of this nuclear receptor.
Peroxisome proliferator-activated receptors (PPARs) areligand-activated nuclear receptors orchestrating the ex-
pression of genes relevant to lipid and glucose metabolism and
occur in three isoforms, alpha, beta, and gamma.1−3 PPAR type
gamma (PPARγ) is most highly expressed in the adipose tissue,
but important functional expression of this receptor has been
also allocated to a variety of nonadipose tissues and cell types,
such as skeletal muscle, liver, pancreatic beta cells, myeloid
dendritic cells, and macrophages.4 PPARγ is the molecular
target of thiazolidinediones (e.g., pioglitazone), used clinically
as insulin sensitizers to lower blood glucose levels in diabetes
type 2 patients.5,6 The thiazolidinedione type of PPARγ ligands
are agonists of the receptor with a very high binding affinity.
However, this ligand type demonstrates a range of undesirable
side effects,7 prompting the search for new PPARγ agonists
effective in the context of lipid and glucose metabolism and
inflammation. Interestingly, recent studies indicate that partial
agonists of PPARγ, inducing submaximal receptor activation,
exhibit very promising activity patterns by retaining the positive
effects attributed to the full agonists but with reduced side
effects.8−10
In recent years, a close interplay between type 2 diabetes and
nonalcoholic fatty liver disease (NAFLD) has been discov-
ered.11 NAFLD is currently the most common cause of liver
disease in the Western world. NAFLD is commonly associated
with insulin resistance, obesity, dyslipidemia, type 2 diabetes,
and cardiovascular disease.12 Therefore, NAFLD is thought to
represent the hepatic manifestation of the metabolic syndrome.
Given the epidemic of obesity and type 2 diabetes, the burden
of NAFLD is expected to continue rising in the near
future.12−14 There is a growing body of evidence that PPARs
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play a role in the pathogenesis of NAFLD and can therefore
serve as targets for its therapy.14−16 PPARs are key modulators
of gene expression and hepatic triglyceride accumulation, and
PPARγ agonists have shown promising results in clinical studies
dealing with the treatment of NAFLD, although more evidence
for their efficacy from larger clinical studies is still
needed.11,12,17
Natural products represent an attractive pool for discovery of
novel bioactive compounds, since they encompass a high
diversity of structural motifs that, as a result of natural selection,
are often evolutionarily optimized to bind to diverse
biomolecules and thereby serve a variety of functions.18 Several
classes of natural products originating from food or medicinal
plants have already been described as PPARγ ligands.9,19−22
Silymarin is a phenolic mixture extracted from milk thistle
[Silybum marianum (L.) Gaertn., Asteraceae] seeds. The major
part (typically 70−80%) of silymarin consists of seven
flavonolignans (i.e., silybin A, silybin B, isosilybin A, isosilybin
B, silychristin, isosilychristin, and silydianin; 1−6) and the
flavonoid taxifolin (7).23 Silybins A and B (1 and 2) and
isosilybins A and B (3 and 4) are two regioisomeric pairs of
diastereomers. Even though they were first described in the
1950s and the diastereomeric mixtures were isolated and
structurally characterized during the 1960s and 1970s,24,25 the
complete isolation and structural characterization of the four
isomers was only achieved in 2003.26,27 Milk thistle fruits and
seeds have been used for more than 2000 years to treat liver
and biliary disorders, and milk thistle seed extracts are still used
in the treatment of some ailments, for example as supportive
agents in hepatitis and cirrhosis therapy.28 Although more
evidence is needed to validate their clinical efficacy in liver
disorders,29−31 milk thistle seed preparations are among the
best-selling herbal products. In the U.S., in 2012, milk thistle
seed preparations ranked sixth of all botanical dietary
supplements sold in food, drug, and mass market outlets,
reaching about $21 million USD in retail sales, a 7.5% increase
over 2011.32 Silymarin and its components display diverse
biological activities in vitro and in vivo, including antioxidant,
membrane-stabilizing, anticholestatic, antifibrotic, antiathero-
genic, anti-inflammatory, anticarcinogenic, and antiviral activity
(against hepatitis C).23,28,33−35 These biological activities are
supposed to be the basis for the therapeutic potential of
silymarin in liver diseases caused by oxidative stress, such as
alcoholic and nonalcoholic fatty liver disease (steatohepatitis)
and drug- and chemical-induced toxicity, in viral-induced
chronic hepatitis, and in primary liver cancer.31
Considering the relevant hepatotherapeutic traditional use of
silymarin, as well as the existing interest in identification of
novel PPARγ ligands, in this study it was aimed to investigate
whether silymarin and its purified flavonolignan and flavonoid
constituents are able to activate PPARγ.
■ RESULTS AND DISCUSSION
Since PPARγ is a key player in several pathways related to
glucose and lipid metabolism, this nuclear receptor constitutes
an important target for drugs used in the treatment of type 2
diabetes and other diseases related to metabolic syndrome such
as NAFLD. To examine whether silymarin, used traditionally
for the treatment of liver disorders, has any PPARγ activation
potential, it was tested in a PPARγ-driven luciferase reporter
gene assay. It exhibited a small but statistically significant
agonistic effect (19% activation at 30 μg/mL, p < 0.05; not
shown). The main constituents in silymarin were quantified by
HPLC analysis and were found to be as follows: 12.7% silybin
A (1), 21.7% silybin B (2), 4.5% isosilybin A (3), 3.1%
isosilybin B (4), 16.1% silychristin (5), 7.1% silydianin (6),
2.6% taxifolin (7). These results are in good accordance with
data published for other commercially available milk thistle
seed extracts.35
When the seven main constituents of silymarin (1−7) were
tested individually in this assay, it turned out that, despite the
high structural similarity of some of the compounds, only
isosilybin A (3) was able to significantly activate PPARγ at a
concentration of 30 μM [2.08 ± 0.48-fold activation, p < 0.01],
while the other tested constituents were inactive (Figure 1).
The fact that the active constituent 3 represents only 4.5% of
the total extract is in accordance with the rather weak activity
observed for silymarin.
In order to explore why only 3, but not its stereo- and
regioisomers, was able to activate PPARγ, docking studies of all
tested compounds within the receptor binding pocket of the
protein were performed (Figure 2). The PPARγ ligand-binding
domain (LBD) has been described previously to possess a Y-
shaped topology: The entrance bears several polar residues
(e.g., Arg288, Glu291, Glu343, and Ser342). The two branches
of the binding pocket, i.e., arm I and arm II, are mainly
composed of hydrophobic residues, with the exception of some
moderately polar residues in arm I (e.g., Cys285, Ser289,
His323, Tyr327, His449, and Tyr473).36 In comparison to the
inactive compounds, isosilybin A (3) formed additional
hydrogen bonds to Ser342 in the entrance and to Tyr327 in
arm I (Figure 2). Due to the distinct configuration at position
7″ of 3, the 4″-hydroxy-3″-methoxyphenyl moiety is able to
form a hydrogen bond with Ser342 in the entrance region. A
hydrophobic moiety and an acceptor site with an appropriate
conformation to establish a hydrogen bond with Ser342 or an
equivalent residue in this part of the PPARγ LBD are regarded
as essential structural features for partial PPARγ agonists that
possess high binding affinity but low transactivation activity in
order to come into consideration as antidiabetic drugs.37 These
modeling results provide a plausible explanation for the fact
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that PPARγ activation was observed only for isosilybin A (3),
but not for its stereo- and regioisomers.
Isosilybin A (3) activated the receptor to a smaller extent
than pioglitazone, a clinically used PPARγ agonist, even at the
highest concentration tested (Figure 3). As can be seen in
Figure 4A, the PPARγ activating effect by 3 (30 μM) and
pioglitazone (5 μM) were inhibited (p < 0.001) when the
PPARγ antagonist T0070907 was added in co-treatment
experiments, confirming the PPARγ dependence of the
measured effects. It is known that partial receptor agonists
often are able to suppress the effects of full agonists upon co-
treatment due to competition for receptor binding. To
investigate whether 3 is able to reduce the effect of the full
PPARγ agonist pioglitazone, the concentration-dependent
effect of pioglitazone was tested in the presence or absence
of 3 (Figure 4B). Indeed, the pioglitazone-mediated PPARγ
activation was clearly reduced in the presence of compound 3.
So far, the positive effects observed for silymarin in clinical
studies associated with diabetes and NAFLD have mainly been
ascribed to its antioxidant and hepatoprotective activity, but
PPARγ activation has not been studied before to the best of our
knowledge.38−41 When analyzing the silymarin preparation
tested by HPLC, it was found that 3 was present in the mixture
at a concentration of only 4.5%. Considering that isosilybin A
(3) constitutes such a minor fraction of silymarin and that the
agonistic properties of this compound seem to be weaker in
comparison to pioglitazone (Figure 3), PPARγ activation
induced by 3 might not be relevant clinically for the therapeutic
use of silymarin. Nevertheless, a contribution of PPARγ
activation by 3 to the in vivo action of silymarin cannot be
completely ruled out, since several partial agonists activating
PPARγ with a weak efficiency in vitro were already
demonstrated to display an array of beneficial PPARγ-
dependent effects when examined in vivo.8,10,22 Since clinically
used PPARγ full agonists of the thiazolidinedione type have a
number of undesirable side effects,7 the identification of novel
PPARγ activators, including partial agonists, is highly
relevant.8−10 While some flavonoids were already reported to
activate PPARγ,42,43 this is the first report demonstrating
PPARγ activation by a flavonolignan-type compound.
In summary, it is reported for the first time that the
flavonolignan isosilybin A (3) from the milk thistle seed extract
Figure 1. PPARγ activation by silymarin constituents. HEK-293 cells
were co-transfected with a plasmid encoding full-length human
PPARγ, a PPAR luciferase reporter plasmid, and EGFP as internal
control. After reseeding, cells were treated as indicated for 18 h. Since
the positive control pioglitazone (5 μM) and the silymarin
constituents (30 μM) were reconstituted in DMSO, cells were treated
with an equal amount of the solvent vehicle DMSO (0.1%) as negative
control. The luciferase activity was normalized to the EGFP-derived
fluorescence, and the result is expressed as fold induction compared to
the solvent vehicle control. The data shown are means ± SD of three
independent experiments each performed in quadruplicate [**p < 0.01
(compared to the solvent vehicle group; n = 3, ANOVA/Bonferroni)].
Figure 2. Predicted binding mode of isosilybin A (3), shown in (A)
3D depiction and (B) 2D depiction. Chemical features are color-
coded: red/green arrow, hydrogen-bond acceptor/donor; yellow
sphere, hydrophobic interaction; surface colored by aggregated
lipophilicity (blue)/hydrophobicity (gray). The favorable interactions
with the water molecule HOH35 and Ser342, which are not observed
in the docking poses for inactive compounds, are suggested to be
responsible for the PPARγ partial activation of isosilybin A (3).
Figure 3. Concentration-dependent PPARγ activition by isosilybin A
(3) and pioglitazone. HEK-293 cells, transiently transfected with a
human PPARγ expression plasmid, a luciferase reporter plasmid (tk-
PPREx3-luc), and EGFP as internal control, were treated with different
concentrations of pioglitazone or isosilybin A (3) for 18 h. Luciferase
activity was normalized by the EGFP-derived fluorescence, and the
result is expressed as fold induction compared to the solvent vehicle
control (0.1% DMSO). The data points shown are means ± SD of
three independent experiments each performed in quadruplicate.
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silymarin acts as a partial PPARγ agonist. Being a new-scaffold
PPARγ activator, 3 might serve as a lead for future development
of new PPARγ agonists. The question as to whether PPARγ
activation by 3 might be clinically relevant for the use of
silymarin as an herbal remedy cannot be conclusively answered
yet and deserves further investigation.
■ EXPERIMENTAL SECTION
Chemicals, Cell Culture Reagents, and Plasmids. Dulbecco’s
modified Eagle’s medium (DMEM), containing 4.5 g/L glucose, and L-
glutamine were purchased from Lonza (Basel, Switzerland). Fetal
bovine serum (FBS) was from Gibco (Lofer, Austria). Silymarin was
purchased from Sigma (SO-292-10g). Taxifolin (7) was purchased
from Roth, Karlsruhe, Germany (5797.2). Compounds 1, 2, 3, and 4
were isolated and structurally identified as described previously.44
Silydianin (6) was isolated and structurally identified as described.45
The isolation of silychristin (5) is described below. The PPARγ
antagonist T0070907 was purchased from Cayman (Ann Arbor, MI,
USA), and pioglitazone was from Molekula Ltd. (Shaftesbury, UK).
Solvents used for HPLC analyses were of gradient grade. The
investigated compounds or dried extracts were dissolved in dimethyl
sulfoxide (DMSO), aliquoted, and stored at −20 °C for further use.
The final concentration of the solvent vehicle DMSO was 0.1% or
lower in all performed experiments. The expression plasmid with
human PPARγ (pSG5-PL-hPPAR-gamma1)46 was provided by Prof.
Beatrice Desvergne and Prof. Walter Wahli (Center for Integrative
Genomics, University of Lausanne, Switzerland), and the luciferase
reporter plasmid (tk-PPREx3-luc)47 was kindly supplied by Prof.
Ronald M. Evans (Salk Institute for Biological Studies, San Diego, CA,
USA). All other chemicals were obtained from Sigma−Aldrich
(Vienna, Austria).
Isolation of Silychristin (5). Isolation was accomplished by
preparative HPLC separation of silymarin on a Varian Prep Star SD-1
solvent delivery system equipped with a Dynamax UV-1 absorbance
detector, which was set to 280 nm. A 100 mg aliquot of silymarin was
dissolved in 0.5 mL of DMSO and 2 mL of methanol and sonicated,
and the solution was centrifuged. An Ultra SEP ES RP-18 column
(250 × 20 mm, 10 μm) was used as a stationary phase, and a gradient
of methanol in water (0−40 min: methanol−water 30:70−55:45; 40−
50 min 55:45−100:0) was used as mobile phase (flow rate: 6 mL/
min). The peak of 5 (tR 38 min) was collected, and the solvent was
evaporated. A yellowish powder (12 mg) was obtained. Its structure
was confirmed by NMR spectroscopy in DMSO-d6 on a Varian Unity
Inova (600 MHz) spectrometer at 25 °C using the parameters
described by Seebacher et al.48 NMR data were found to be in
accordance with those values published for 5 by Kim et al.49
HPLC Quantification of Silymarin Constituents. HPLC
measurements were performed on an Agilent 1260 HPLC-DAD
instrument. As a stationary phase, a Zorbax SB-C18 column (2.1 × 150
mm, 3.5 μm) protected by a Zorbax SB-C8 guard column (2.1 × 12.5
mm, 5 μm) (both Agilent Technologies) was used. The mobile phase
consisted of water + 0.1% HCOOH (solvent A) and methanol + 0.1%
HCOOH (solvent B). The following gradient was used: 0−30 min
A:B 70:30−45:55; 30−40 min A:B 45:55−20:80; 40−45 min A:B
20:80−0:100; 45−46 min A:B 0:100−70:30; 46−55 min A:B 70:30.
The flow rate was 230 μL/min, the column temperature was 20 °C,
and a detector wavelength of 280 nm was used for quantification.
Silymarin was dissolved in methanol (2.5 mg/mL). For HPLC
analysis, 5 μL was injected. For the preparation of calibration curves,
reference compounds were dissolved in methanol (1 mg/mL) and
serially diluted (0.002 to 1 mg/mL; five concentrations for each
compound). From each concentration, 5 μL was injected for HPLC
analysis. The purity of the reference compounds used was in the range
93.4−95.8%. All calibration curves showed good linearity (R2 > 0.994).
PPARγ Luciferase Reporter Transactivation. HEK-293 cells
(ATCC, Rockville, MD, USA) were maintained in 75 cm2 flasks at 37
°C and 5% CO2, in DMEM with phenol red, with 100 U/mL
benzylpenicillin, 100 μg/mL streptomycin, 10% FBS, and 2 mM L-
glutamine. The assay was performed as described previously.9,20
Briefly, cells were seeded in 10 cm dishes and transiently transfected
by the calcium phosphate precipitation method50 with 4 μg of the
reporter plasmid (tk-PPREx3-luc), 4 μg of the PPARγ expression
plasmid (pSG5-PL-hPPAR-gamma1), and 2 μg of green fluorescent
protein plasmid (pEGFP-N1, Clontech, Mountain View, CA, USA) as
internal control. Transfected cells were reseeded in 96-well plates,
treated with the indicated compounds or the solvent vehicle (0.1%
DMSO), and incubated for 18 h. The cells were then lysed with a
reporter lysis buffer (E3971, Promega, Madison, WI, USA). Luciferase
activity was evaluated using a GeniosPro plate reader (Tecan, Grödig,
Austria), and EGFP-derived fluorescence was used for normalization,
to account for differences in the transfection efficiency or cell number.
Docking Study. In order to surmise the binding mode of the main
silymarin constituents, a docking study was performed. Basically, in
this docking study the quantum mechanics-polarized ligand docking
(QPLD) workflow,51 available within the Maestro suite version
9.2.112 (Schrödinger, LLC, New York, NY, 2011, http://schrodinger.
com), was employed. Briefly, the ligand and protein preparation as
Figure 4. PPARγ-dependence and co-treatment experiments. (A)
HEK-293 cells, transiently transfected with a human PPARγ
expression plasmid, a luciferase reporter plasmid (tk-PPREx3-luc),
and EGFP as internal control, were treated for 18 h with pioglitazone
(5 μM), T0070907 (1 μ M), isosilybin A (3; 30 μM), or combinations
as indicated on the x-axis. Luciferase activity was normalized by the
EGFP-derived fluorescence, and the results are expressed as fold
induction compared to the solvent vehicle control (DMSO, 0.1%).
The data points shown are means ± SD of three independent
experiments each performed in quadruplicate [**p < 0.01; ***p <
0.001 (n = 3, ANOVA/Bonferroni)]. (B) Cells were transfected as
indicated above. Pioglitazone was applied in different concentrations in
the presence and absence of 30 μM isosilybin A (3). The data shown
are means ± SD of three independent experiments each performed in
quadruplicate.
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well as the protein−ligand docking were performed in a comparable
manner to a previous investigation, which was conducted to propose
the binding modes of polyacetylene-type partial PPARγ agonists from
natural sources.20 For the docking, the X-ray crystal structure of the
LBD of PPARγ in complex with two copies of magnolol, a natural
product PPARγ partial agonist, was used (Protein Data Bank52 entry:
3r5n53). The docking poses were postprocessed by (i) the insertion of
the water molecule HOH35 into the LBD (which to our best
knowledge occasionally has a critical role by mediating interactions
from this nuclear receptor to ligands, especially when partial agonists
are involved) and (ii) the MMFF94-based minimization within
LigandScout 3.1 (Inte:Ligand, GmbH, Maria Enzersdorf, Austria,
2012, http://www.inteligand.com), which was also used for visual-
ization purposes.
Statistical Methods and Data Analysis. All statistical analyses
were done with the GraphPad Prism software version 4.03. At least
three independent experiments were performed, and one-way analysis
of variance (ANOVA) with a Bonferroni post hoc test was used to
determine statistical significance. Data with p < 0.05 were considered
as significantly different.
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and H. Beres is gratefully acknowledged. This work was
supported financially by the Austrian Science Fund (FWF):
S10704, S10705, and S10711 (NFN-project “Drugs from
Nature Targeting Inflammation”). The isolation of compounds
1, 2, 3, and 4 was supported in part by the National Institutes
of Health/National Center for Complementary and Alternative
Medicine via grant R01 AT006842. We acknowledge
Inte:Ligand GmbH for providing LigandScout free of charge
for this study. We thank Prof. W. Wahli and Prof. B. Desvergne
(Center for Integrative Genomics, University of Lausanne,
Switzerland), as well as Prof. R. M. Evans (Howard Hughes
Medical Institute, California), for providing us with the PPAR
expression plasmids and the PPRE luciferase reporter construct,
respectively.
■ REFERENCES
(1) Evans, R. M.; Barish, G. D.; Wang, Y. X. Nat. Med. 2004, 10,
355−361.
(2) Vacca, M.; Degirolamo, C.; Mariani-Costantini, R.; Palasciano,
G.; Moschetta, A. Wiley Interdiscipl. Rev. Syst. Biol. Med. 2011, 3, 562−
587.
(3) Desvergne, B.; Michalik, L.; Wahli, W. Physiol. Rev. 2006, 86,
465−514.
(4) Ahmadian, M.; Suh, J. M.; Hah, N.; Liddle, C.; Atkins, A. R.;
Downes, M.; Evans, R. M. Nat. Med. 2013, 19, 557−566.
(5) Lehmann, J. M.; Moore, L. B.; Smith-Oliver, T. A.; Wilkison, W.
O.; Willson, T. M.; Kliewer, S. A. J. Biol. Chem. 1995, 270, 12953−
12956.
(6) Lalloyer, F.; Staels, B. Arterioscler. Thromb. Vasc. Biol. 2010, 30,
894−899.
(7) Rubenstrunk, A.; Hanf, R.; Hum, D. W.; Fruchart, J. C.; Staels, B.
Biochim. Biophys. Acta 2007, 1771, 1065−1081.
(8) Agrawal, R.; Jain, P.; Dikshit, S. N. Mini Rev. Med. Chem. 2012,
12, 87−97.
(9) Atanasov, A. G.; Wang, J. N.; Gu, S. P.; Bu, J.; Kramer, M. P.;
Baumgartner, L.; Fakhrudin, N.; Ladurner, A.; Malainer, C.; Vuorinen,
A.; Noha, S. M.; Schwaiger, S.; Rollinger, J. M.; Schuster, D.; Stuppner,
H.; Dirsch, V. M.; Heiss, E. H. Biochim. Biophys. Acta 2013, 1830,
4813−4819.
(10) Bhalla, K.; Hwang, B. J.; Choi, J. H.; Dewi, R.; Ou, L.;
McLenithan, J.; Twadell, W.; Pozharskiy, E.; Stock, J.; Girnun, G. J.
Biol. Chem. 2011, 286, 41626−41635.
(11) Williams, K. H.; Shackel, N. A.; Gorrell, M. D.; McLennan, S.
V.; Twigg, S. M. Endocr. Rev. 2013, 34, 84−129.
(12) Lomonaco, R.; Sunny, N. E.; Bril, F.; Cusi, K. Drugs 2013, 73,
1−14.
(13) Tarantino, G.; Saldalamacchia, G.; Conca, P.; Arena, A. J.
Gastroenterol. Hepatol. 2007, 22, 293−303.
(14) Kallwitz, E. R.; McLachlan, A.; Cotler, S. J. World J.
Gastroenterol. 2008, 14, 22−28.
(15) Seo, Y. S.; Kim, J. H.; Jo, N. Y.; Choi, K. M.; Baik, S. H.; Park, J.
J.; Kim, J. S.; Byun, K. S.; Bak, Y. T.; Lee, C. H.; Kim, A.; Yeon, J. E. J.
Gastroenterol. Hepatol. 2008, 23, 102−109.
(16) Kim, M. S.; Kung, S.; Grewal, T.; Roufogalis, B. D. Curr. Pharm.
Biotechnol. 2012, 13, 278−291.
(17) Smith, B. W.; Adams, L. A. Nat. Rev. Endocrinol. 2011, 7, 456−
465.
(18) Newman, D. J.; Cragg, G. M. J. Nat. Prod. 2012, 75, 311−335.
(19) Marion-Letellier, R.; Dechelotte, P.; Iacucci, M.; Ghosh, S. Gut
2009, 58, 586−593.
(20) Atanasov, A. G.; Blunder, M.; Fakhrudin, N.; Liu, X.; Noha, S.
M.; Malainer, C.; Kramer, M. P.; Cocic, A.; Kunert, O.; Schinkovitz,
A.; Heiss, E. H.; Schuster, D.; Dirsch, V. M.; Bauer, R. PLoS One 2013,
8, e61755.
(21) Fakhrudin, N.; Ladurner, A.; Atanasov, A. G.; Heiss, E. H.;
Baumgartner, L.; Markt, P.; Schuster, D.; Ellmerer, E. P.; Wolber, G.;
Rollinger, J. M.; Stuppner, H.; Dirsch, V. M. Mol. Pharmacol. 2010, 77,
559−566.
(22) Weidner, C.; de Groot, J. C.; Prasad, A.; Freiwald, A.;
Quedenau, C.; Kliem, M.; Witzke, A.; Kodelja, V.; Han, C. T.; Giegold,
S.; Baumann, M.; Klebl, B.; Siems, K.; Muller-Kuhrt, L.; Schurmann,
A.; Schuler, R.; Pfeiffer, A. F.; Schroeder, F. C.; Bussow, K.; Sauer, S.
Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 7257−7262.
(23) Polyak, S. J.; Ferenci, P.; Pawlotsky, J. M. Hepatology 2013, 57,
1262−1271.
(24) Pelter, A.; Han̈sel, R. Tetrahedron Lett. 1968, 9, 2911−2916.
(25) Arnone, A.; Merlini, L.; Zanarotti, A. J. Chem. Soc., Chem.
Commun. 1979, 696−697.
(26) Kim, N. C.; Graf, T. N.; Sparacino, C. M.; Wani, M. C.; Wall, M.
E. Org. Biomol. Chem. 2003, 1, 1684−1689.
(27) Lee, D. Y.; Liu, Y. J. Nat. Prod. 2003, 66, 1171−1174.
(28) Post-White, J.; Ladas, E. J.; Kelly, K. M. Integr. Cancer Ther.
2007, 6, 104−109.
(29) Rambaldi, A.; Jacobs, B. P.; Gluud, C. Cochrane Database Syst.
Rev. 2007, CD003620.
(30) ESCOP Monographs, 2nd ed.; 2009; pp 222−248.
(31) Feher, J.; Lengyel, G. Curr. Pharm. Biotechnol. 2012, 13, 210−
217.
(32) Lindstrom, A.; Ooyen, C.; Lynch, M. E.; Blumenthal, M.
HerbalGram 2013, 99, 60−65.
(33) Polyak, S. J.; Morishima, C.; Lohmann, V.; Pal, S.; Lee, D. Y.;
Liu, Y.; Graf, T. N.; Oberlies, N. H. Proc. Natl. Acad. Sci. U.S.A. 2010,
107, 5995−5999.
(34) Saller, R.; Meier, R.; Brignoli, R. Drugs 2001, 61, 2035−2063.
(35) Davis-Searles, P. R.; Nakanishi, Y.; Kim, N. C.; Graf, T. N.;
Oberlies, N. H.; Wani, M. C.; Wall, M. E.; Agarwal, R.; Kroll, D. J.
Cancer Res. 2005, 65, 4448−4457.
(36) Zoete, V.; Grosdidier, A.; Michielin, O. Biochim. Biophys. Acta
2007, 1771, 915−925.
Journal of Natural Products Article
dx.doi.org/10.1021/np400943b | J. Nat. Prod. 2014, 77, 842−847846
(37) Guasch, L.; Sala, E.; Valls, C.; Blay, M.; Mulero, M.; Arola, L.;
Pujadas, G.; Garcia-Vallve, S. J. Comput.-Aided Mol. Des. 2011, 25,
717−728.
(38) Yeh, G. Y.; Eisenberg, D. M.; Kaptchuk, T. J.; Phillips, R. S.
Diabetes Care 2003, 26, 1277−1294.
(39) Huseini, H. F.; Larijani, B.; Heshmat, R.; Fakhrzadeh, H.;
Radjabipour, B.; Toliat, T.; Raza, M. Phytother. Res. 2006, 20, 1036−
1039.
(40) Abenavoli, L.; Milic, N.; Capasso, F. Endocrine 2012, 42, 754−
755.
(41) Chang, C. L.; Chen, Y. C.; Chen, H. M.; Yang, N. S.; Yang, W.
C. Curr. Med. Chem. 2013, 20, 899−907.
(42) Ortuno-Sahagun, D.; Marquez-Aguirre, A. L.; Quintero-Fabian,
S.; Lopez-Roa, R. I.; Rojas-Mayorquin, A. E. PPAR Res. 2012, 318613.
(43) Penumetcha, M.; Santanam, N. PPAR Res. 2012, 858352.
(44) Graf, T. N.; Wani, M. C.; Agarwal, R.; Kroll, D. J.; Oberlies, N.
H. Planta Med. 2007, 73, 1495−1501.
(45) Wagner, H.; Seligmann, O.; Seitz, M.; Abraham, D.;
Sonnenbichler, J. Z. Naturforsch. B 1976, 31, 876−884.
(46) Peyrin-Biroulet, L.; Beisner, J.; Wang, G.; Nuding, S.; Oommen,
S. T.; Kelly, D.; Parmentier-Decrucq, E.; Dessein, R.; Merour, E.;
Chavatte, P.; Grandjean, T.; Bressenot, A.; Desreumaux, P.; Colombel,
J. F.; Desvergne, B.; Stange, E. F.; Wehkamp, J.; Chamaillard, M. Proc.
Natl. Acad. Sci. U.S.A. 2010, 107, 8772−8777.
(47) Kliewer, S. A.; Umesono, K.; Noonan, D. J.; Heyman, R. A.;
Evans, R. M. Nature 1992, 358, 771−774.
(48) Seebacher, W.; Simic, N.; Weis, R.; Saf, R.; Kunert, O. Magn.
Reson. Chem. 2003, 41, 636−638.
(49) Kim, N. C.; Graf, T. N.; Sparacino, C. M.; Wani, M. C.; Wall, M.
E. Org. Biomol. Chem. 2003, 1, 1684−1689.
(50) Graham, F. L.; van der Eb, A. J. Virology 1973, 52, 456−467.
(51) Chung, J. Y.; Hah, J. M.; Cho, A. E. J. Chem. Inf. Model. 2009,
49, 2382−2387.
(52) Berman, H. M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.
N.; Weissig, H.; Shindyalov, I. N.; Bourne, P. E. Nucleic Acids Res.
2000, 28, 235−242.
(53) Zhang, H.; Xu, X.; Chen, L.; Chen, J.; Hu, L.; Jiang, H.; Shen, X.
PLoS One 2011, 6, e28253.
Journal of Natural Products Article
dx.doi.org/10.1021/np400943b | J. Nat. Prod. 2014, 77, 842−847847
